
ZBH Stock Forecast & Price Target
ZBH Analyst Ratings
Bulls say
Zimmer Biomet Holdings (ZBH) demonstrates a positive outlook due to its significant market share growth in the global reconstructive market, with a year-over-year increase of approximately 20 basis points, bringing its share to 32.9%. The company reported strong sales performance in its knee and hip segments, with knee sales reaching $911 million and hip sales totaling $555 million, both exceeding consensus estimates and showing improvements from the previous quarter. Additionally, the firm experienced operational margin expansion, building from a reported 28.6% for FY24, reflecting its effective cost management and growth strategies.
Bears say
The analysis of Zimmer Biomet Holdings (ZBH) highlights a concerning trend of declining organic revenue growth, marked by a slowdown over the past eight quarters that is expected to persist into 2026. Additionally, the underperformance of Paragon 28 and limited contributions from new product launches have constrained potential growth, which is now projected to slump to 2% or less. Compounding these issues, ZBH has experienced a deterioration in its operating margin, exacerbated by increased selling, general, and administrative (SG&A) expenses, indicating challenges that could lead to below-consensus earnings.
This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.
ZBH Analyst Forecast & Price Prediction
Start investing in ZBH
Order type
Buy in
Order amount
Est. shares
0 shares